Circovirus

It’s one of the most devastating and economically damaging pig diseases in the world: Porcine circovirus associated disease (PCVAD). It can strike early or appear in a late form. And once it strikes, the consequences are never good.

Circovirus

BOEHRINGER INGELHEIM 2008 PCVAD RESEARCH AWARD

Boehringer Ingelheim Vetmedica, Inc., (BIVI) announces the recipients of its annual research award program directed at porcine circovirus associated disease (PCVAD). The $75,000 PCVAD Research Awards will fund three research studies designed to improve the industry’s understanding and management of this devastating disease.

Circovirus

EUROPEAN PCV2 RESEARCH AWARDS

EU - The EU PCVD Consortium announced awards for Professor Hans Nauwynck and Professor Joaquim Segalés in its June 2008 newsletter.

Circovirus

FIRST EVER EUROPEAN PCV2-RESEARCH AWARD WINNERS HONOURED

GERMANY - Prof. Hans Nauwynck, Prof. Joaquim Segalés, Danja Wiederkehr together and Dr. Xaver Sidler are the first ever winners of the European PCV2 Research Award

Circovirus

CIRCOVIRUS VACCINE RECEIVES FOUR-MONTH DURATION OF IMMUNITY APPROVAL

US - Boehringer Ingelheim Vetmedica, Inc., (BIVI) has announced that the U.S. Animal and Plant Health Inspection Service has approved a duration of immunity (DOI) claim for Ingelvac® CircoFLEX™ of at least four months for porcine circovirus type 2 (PCV2), the primary pathogen for porcine circovirus associated disease (PCVAD).